MAP2K7 and hepatocellular carcinoma: Noteworthy, Li et al. experimentally unraveled that YRDC, serving as a subunit of the KEOPS complex by combining with OSGEP, could promote the progression of hepatocellular carcinoma (HCC) via modulating the MEK/ERK signaling pathway [23].